webinar register page

Webinar banner
NeoGenomics Lung Cancer Tumor Board
NeoGenomics is proud to offer our Molecular Tumor Boards covering relevant topics in cancer care. In each session, multidisciplinary teams will submit and discuss 2 - 4 patients with expert oncologists.

To submit cases for discussion, please reach out to tumorboards@neogenomics.com.
Aug 3, 2022 09:00 AM
Sep 7, 2022 09:00 AM
Nov 2, 2022 09:00 AM
Time shows in
Webinar logo
* Required information
Loading

Speakers

Narjust Duma, MD
Associate Director of the Cancer Care Equity Program @Dana-Farber Cancer Institute/Harvard Cancer Center
Dr. Duma is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Cancer Institute/Harvard Cancer Center. Her clinical interests include targeted therapy for lung cancer and the care of women with lung cancer, including their unique aspects of cancer survivorship. She is the founder of the Duma Lab in 2019 that focuses on lung cancer, social justices issues in medicine and medical education and the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) study, the largest study to date evaluating sexual dysfunction in women with lung cancer. Dr. Duma is the recipient of the Mayo Brothers Distinguished Fellowship Award at the Mayo Clinic School of Graduate Medical Education; the Merit Award/ASCO Employees Endowed Merit Award; the Next-Generation Innovators Award, as well as many other awards.
Rodolfo Bordoni, MD
Medical Oncologist and Director of the Clinical Research Program @Georgia Cancer Specialists
Dr. Bordoni is the Director of the Clinical Research Program for Georgia Cancer Specialists.  He is the founder and former co-Chair of the annual Atlanta Lung Cancer Symposium and the founder and Chair of the Atlanta Precision Oncology Symposium. He has been a National Cancer Institute investigator since 1992, the Principal Investigator for over sixty oncology clinical trials, a Leader of the Northside Hospital and Cancer Institute Lung Cancer Research Working Group from 2014 thru 2020, and a member of the Northside Hospital and Cancer Institute Multidisciplinary Thoracic Oncology Group. He is also the Director of the Phase I clinical trials program at GCS and Northside Hospital Cancer Institute. He is an active member of the American Society of Clinical Oncology (ASCO) and the International Association for the Study of Lung Cancer (IASLC).
Hatim Husain, MD
Associate Professor of Medicine @UC San Diego Health
Dr. Husain is a board-certified medical oncologist who specializes in treating lung cancer and brain tumors. In addition to instructing medical students, residents and fellows, he is also a physician-scientist dedicated to understanding the cancer genome and how to advance meaningful, precision-oriented therapies for patients. Dr. Husain has developed a translational research focus and collaborates with scientists to bring discoveries from bench-to-bedside. His efforts include expanding tools for tracking cancer growth specifically through circulating tumor DNA analyses; understanding the mechanisms of cancer formation in non-smoking patients; and investigating how the genome can provide clues to optimal treatments and new therapies. He completed a fellowship in medical oncology at Johns Hopkins School of Medicine and a residency in internal medicine at Keck School of Medicine of USC. Dr. Husain earned his medical degree from Northwestern University Feinberg School of Medicine.